ProMIS Neurosciences (NasdaqCM:PMN) FY Conference Transcript

Summary of ProMIS Neurosciences FY Conference Call Company Overview - Company: ProMIS Neurosciences (NasdaqCM:PMN) - Focus: Development of novel drugs for Alzheimer's disease, specifically targeting amyloid beta oligomers Industry Insights - Alzheimer's Disease Landscape: - Current treatments have a risk-benefit profile that is not favorable, leading to challenges in prescription by physicians [2][3] - There is a significant opportunity for novel drugs that effectively target the harmful species of amyloid beta [3] Key Developments - Clinical Trials: - ProMIS is conducting a Phase 1b trial for its lead compound, PMN310, an amyloid beta monoclonal antibody [4][6] - The trial is on track for complete enrollment of 128 patients by the end of the year, with an interim analysis expected in Q2 of the following year [4][5][19] - Final top-line results are anticipated in Q4 of next year [5] Product Differentiation - Targeting Strategy: - PMN310 focuses on low molecular weight oligomers of amyloid beta, which are believed to be the most toxic and drive disease progression [10][14] - The industry has shifted away from targeting plaque forms of amyloid beta due to limited clinical benefits [9][10] Safety Profile - Safety and Efficacy: - The trial has shown a clean safety profile to date, with expectations to maintain low levels of ARIA (Amyloid-related imaging abnormalities) incidents [16][18] - The dropout rate in the trial is significantly lower than in other studies, indicating strong patient retention [15] Biomarker Analysis - Interim Analysis: - The interim analysis will focus on safety, biomarkers, and clinical endpoints, with specific biomarkers like pTau217 and neurogranin being key indicators of disease progression and neuroinflammation [20][21] - A recent study highlighted the predictive value of pTau217 for clinical outcomes, which may influence future regulatory considerations [22][25] Regulatory Considerations - FDA Approval Pathway: - The FDA has moved away from approving drugs based solely on plaque reduction, emphasizing the need for clinically validated endpoints [24][25] - There is uncertainty regarding whether pTau217 will be accepted as a valid biomarker for approval, as the FDA may continue to prioritize clinical endpoints [25][26] Future Directions - Potential for Subcutaneous Delivery: - The decision to pursue a subcutaneous formulation will likely be made after the interim analysis, depending on the efficacy and safety data [40][41] - The current formulation allows for monthly dosing, and if successful, a subcutaneous option could be developed in parallel with ongoing studies [41][42] Conclusion - ProMIS Neurosciences is positioned to potentially make significant contributions to the Alzheimer's treatment landscape with its innovative approach to targeting amyloid beta oligomers. The upcoming interim analysis and final results will be critical in determining the future trajectory of PMN310 and its market positioning.